Albert Bourla, Pfizer's COO, ticked off Xtandi's perceived advantages during the company's fourth-quarter earnings call. "There are differences between Xtandi and Zytiga safety, there are differences in terms of dosing frequency, there are differences in terms of requirements for steroid administration, and there are also very different monitoring acquirements," Bourla said, according to a Seeking Alpha transcript. He went on to tout the company's FDA filing for a new indication based on the Prosper data. Xtandi is also at the center of "more studies that are coming in the earlier setting," Bourla noted.